-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RioDerm-002 in Radiation Injury
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RioDerm-002 in Radiation Injury report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RioDerm-002 in Radiation Injury Drug Details: RioDerm-002 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RioDerm-003 in Radiodermatitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RioDerm-003 in Radiodermatitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RioDerm-003 in Radiodermatitis Drug Details: RioDerm-003 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Leronlimab in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Leronlimab in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Leronlimab in Triple-Negative Breast Cancer (TNBC) Drug Details: Leronlimab (PRO-140)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Leronlimab in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Leronlimab in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Leronlimab in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: Leronlimab (PRO-140)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PEP-010 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PEP-010 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PEP-010 in Solid Tumor Drug Details: PEP-010 (DPTC-9h) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PEP-07 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PEP-07 in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PEP-07 in Mantle Cell Lymphoma Drug Details: PEP-07 (CASC-578) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PEP-07 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PEP-07 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PEP-07 in Refractory Acute Myeloid Leukemia Drug Details: PEP-07 (CASC-578)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PEP-07 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PEP-07 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PEP-07 in Relapsed Acute Myeloid Leukemia Drug Details: PEP-07 (CASC-578)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Wound Healing in Wounds
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Wound Healing in Wounds Drug Details: Biologic is under development for the treatment of wound healing....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acute Myocardial Infarction in Myocardial Infarction
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Acute Myocardial Infarction in Myocardial Infarction Drug Details: Biologic is under development for the treatment...